Affiliation:
1. Drug Discovery and Development Research Group, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada
Abstract
There is a need for novel antiepileptic agents whose modes of action differ from those of current antiepileptic drugs. The objective of this study was to determine whether 1-diethylamino-3-phenylprop-2-en-1-one (2) could prevent or at least diminish convulsions caused by different mechanisms. This amide afforded protection in the maximal electroshock and subcutaneous pentylenetetrazole screens when given intraperitoneally to both mice and rats. A number of specialized tests in mice were conducted and are explained in the text. They revealed (2) to have efficacy in the 6 Hz psychomotor seizure test, the corneal kindling model, the mouse temporal epilepsy screen and a peripheral neuronal transmission test using formalin. Three screens in rats were undertaken, which revealed that (2) blocked chloride channels, inhibited peripheral neuronal transmission (tested using sciatic ligation and von Frey fibres) and afforded protection in the lamotrigine-resistant kindled rat model. The biodata generated reveal that (2) is an important lead molecule in the quest for novel structures to combat epilepsy.
Funder
Purdue Neuroscience Company, U.S.A
Reference21 articles.
1. New Trends and Most Promising Therapeutic Strategies for Epilepsy Treatment;Riva;Front. Neurol.,2021
2. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options;Potschka;Pharmacol. Rev.,2020
3. Design, synthesis, and pharmacological evaluation of aryl oxadiazole linked 1,2,4-triazine derivatives as anticonvulsant agents;Grover;Med. Chem. Res.,2022
4. Design, Synthesis, and Docking Study of Pyrimidine-Triazine Hybrids for GABA Estimation in Animal Epilepsy Models: Pyrimidine-Triazine Hybrids as Anticonvulsants;Sahu;Arch. Pharm.,2017
5. Anticonvulsants containing the N-(3-aryl-2-propenyl)amido pharmacophore;Dimmock;J. Enz. Inhib. Med. Chem.,2004